Free tool
FAERS Monitor: Methylin
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021475 or its brand name (Methylin, Methylphenidate Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
7,558
Serious
4,673
62% of reports
Hospitalization
1,788
Death reported
508
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective1,100
- headache416
- fatigue384
- anxiety381
- off label use376
- nausea355
- toxicity to various agents343
- drug abuse307
- product substitution issue296
- somnolence285
- insomnia281
- disturbance in attention256
- decreased appetite243
- agitation237
- suicidal ideation234
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 6 |
| 2005 | 7 |
| 2006 | 5 |
| 2007 | 15 |
| 2008 | 23 |
| 2009 | 73 |
| 2010 | 82 |
| 2011 | 55 |
| 2012 | 128 |
| 2013 | 151 |
| 2014 | 149 |
| 2015 | 484 |
| 2016 | 422 |
| 2017 | 532 |
| 2018 | 604 |
| 2019 | 480 |
| 2020 | 361 |
| 2021 | 412 |
| 2022 | 615 |
| 2023 | 796 |
| 2024 | 748 |
| 2025 | 729 |
| 2026 | 681 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,046,601 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| product substitution issueSignal | 296 | 14.4 | 12.9 | 3,662 |
| disturbance in attentionSignal | 256 | 13.3 | 11.8 | 2,885 |
| drug abuseSignal | 307 | 10.3 | 9.2 | 2,569 |
| agitationSignal | 237 | 9.0 | 7.9 | 1,679 |
| suicidal ideationSignal | 234 | 7.1 | 6.3 | 1,229 |
| toxicity to various agentsSignal | 343 | 5.7 | 5.1 | 1,322 |
| somnolenceSignal | 285 | 3.9 | 3.5 | 628 |
| anxietySignal | 381 | 3.7 | 3.4 | 768 |
| insomniaSignal | 281 | 2.9 | 2.6 | 361 |
| decreased appetiteSignal | 243 | 2.9 | 2.6 | 307 |
| drug ineffectiveSignal | 1,100 | 2.3 | 2.2 | 883 |
| headache | 416 | 1.8 | 1.7 | 166 |
| fatigue | 384 | 1.4 | 1.2 | 40 |
| nausea | 355 | 1.2 | 1.1 | 18 |
| off label use | 376 | 1.2 | 1.1 | 12 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.